These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6307874)

  • 21. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses.
    Wu CY; Chang CY; Ma HH; Wang CW; Chen YT; Hsiao PW; Chang CC; Chan CH; Liu CC; Chen JR
    Vaccine; 2014 Jul; 32(35):4485-4494. PubMed ID: 24962757
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection.
    Willey DE; Cantin EM; Hill LR; Moss B; Notkins AL; Openshaw H
    J Infect Dis; 1988 Dec; 158(6):1382-6. PubMed ID: 2848904
    [No Abstract]   [Full Text] [Related]  

  • 23. Herpes simplex virus subunit vaccine: characterization of the virus strain used and testing of the vaccine.
    Hilfenhaus J; Moser H; Herrmann A; Mauler R
    Dev Biol Stand; 1982; 52():321-31. PubMed ID: 6299841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted.
    Farrell HE; McLean CS; Harley C; Efstathiou S; Inglis S; Minson AC
    J Virol; 1994 Feb; 68(2):927-32. PubMed ID: 8289395
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of new adjuvants in an emergency vaccine against foot-and-mouth disease virus: evaluation of conferred immunity.
    Quattrocchi V; Bianco V; Fondevila N; Pappalardo S; Sadir A; Zamorano P
    Dev Biol (Basel); 2004; 119():481-97. PubMed ID: 15742663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice.
    Suschak JJ; Bagley K; Six C; Shoemaker CJ; Kwilas S; Spik KW; Dupuy LC; Schmaljohn CS
    Antiviral Res; 2018 Nov; 159():113-121. PubMed ID: 30268913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
    Berman PW; Gregory T; Crase D; Lasky LA
    Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.
    Burke RL; Goldbeck C; Ng P; Stanberry L; Ott G; Van Nest G
    J Infect Dis; 1994 Nov; 170(5):1110-9. PubMed ID: 7963702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpes simplex virus vaccine: protection from stomatitis, ganglionitis, encephalitis and latency.
    Kitces EN; Payne WJ; Morahan PS; Tew JG; Murray BK
    IARC Sci Publ (1971); 1978; (24 Pt 2):1027-32. PubMed ID: 221370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
    Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
    J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles.
    Jiang B; Estes MK; Barone C; Barniak V; O'Neal CM; Ottaiano A; Madore HP; Conner ME
    Vaccine; 1999 Feb; 17(7-8):1005-13. PubMed ID: 10067709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
    Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
    Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of antibody responses to veterinary vaccine antigens potentiated by different adjuvants.
    Usinger WR
    Vaccine; 1997 Dec; 15(17-18):1902-7. PubMed ID: 9413100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunomodulatory effects of HSV2 glycoprotein D in HSV1 infected mice: implications for immunotherapy of recurrent HSV infection.
    York LJ; Giorgio DP; Mishkin EM
    Vaccine; 1995 Dec; 13(17):1706-12. PubMed ID: 8719523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herpes simplex virus vaccines.
    Bernstein DI; Stanberry LR
    Vaccine; 1999 Mar; 17(13-14):1681-9. PubMed ID: 10194823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.
    Hook LM; Awasthi S; Dubin J; Flechtner J; Long D; Friedman HM
    Vaccine; 2019 Jan; 37(4):664-669. PubMed ID: 30551986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
    Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
    Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.